How does the new HIV vaccine aim to differ from current treatments?

Question

Accepted Answer

New HIV Vaccine Aims for Sustained Treatment-Free Control, Moving Beyond Viral Suppression

The research project investigating the PD-1-enhanced DNA vaccine ICVAX seeks to achieve sustained control of HIV-1 without the need for current combination antiretroviral therapy (cART). Unlike cART, which primarily focuses on suppressing viral reproduction, this novel approach aims to enhance the body's immune system to manage the virus long-term, potentially leading to a functional cure for HIV/AIDS.
Enhancing Immunogenicity for Treatment Interruption

A key objective of the research is to determine the feasibility of analytical treatment interruption (ATI) among people living with HIV-1 (PLWH) who have participated in the ICVAX Phase 1 Trial. This involves assessing whether the immune system, boosted by the ICVAX vaccine, can maintain viral control after standard cART is stopped. The project also plans to optimize ICVAX's immunogenicity through a multi-centre Phase 2 Trial, aiming to elicit a more robust and sustained immune response.
Investigating Immune Protection Mechanisms

The research will delve into the mechanisms by which the PD-1-enhanced DNA vaccine ICVAX induces immune protection. Preliminary Phase 1 Trial data has already demonstrated that ICVAX shows convincing safety and immunogenicity profiles in PLWH. By further investigating these aspects, scientists hope to understand how the vaccine primes the immune system to recognize and control HIV-1, potentially paving the way for alternative treatment strategies that do not rely on lifelong cART.
Developing a "Made in Hong Kong" Immunotherapy

The project aims to reveal the underlying mechanisms of this promising immunotherapy, developed in Hong Kong, as it progresses through clinical trials. The ultimate goal is to contribute to a better understanding of long-term viral control and explore the potential of ICVAX, in combination with other complementary strategies, as a viable alternative treatment for HIV-1, moving towards a future where sustained cART-free control is achievable.

Reading history

Hide →

This history is cleared when the page is closed.

How does the new HIV vaccine aim to differ from current treatments?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends